VEGFA and melanoma: This modest efficacy was not as promising as previous results in murine melanoma and ovarian cancer,19, 20, 21 probably due to the weakly immunogenic and highly aggressive nature of the 4T1 tumors.43 Another potential explanation for the lower efficacy of CPMV against 4T1 tumors compared to B16F10 melanoma and ID8/Vegf/Defb29 ovarian tumors is the different mouse strains used as tumor models.